Interpretation systems for genotypic drug resistance of HIV-1

Scandinavian Journal of Infectious Diseases, Supplement

Volumn , Issue 106, 2003, Pages 29-34

  De Luca, Andrea ^a   Antinori, Andrea ^b   Di Giambenedetto, Simona ^a   Cingolani, Antonella ^a   Colafigli, Manuela ^a   Perno, Carlo Federico ^b   Cauda, Roberto ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; VIRUS ENZYME; ZALCITABINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; VIRUS DNA;

ACCESS TO INFORMATION; AMINO ACID SUBSTITUTION; ANTIVIRAL ACTIVITY; AUTOMATION; COMPUTER PROGRAM; CONTROLLED STUDY; DRUG SENSITIVITY; DRUG TARGETING; GENETIC ALGORITHM; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERNET; PHENOTYPE; REVIEW; TREATMENT FAILURE; VALIDATION PROCESS; ANTIBIOTIC RESISTANCE; BIOLOGY; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; FEMALE; GENETICS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; MALE; METHODOLOGY; MICROBIOLOGICAL EXAMINATION; PHARMACOGENETICS; RANDOMIZED CONTROLLED TRIAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; STANDARD;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COMPUTATIONAL BIOLOGY; DNA, VIRAL; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; PHARMACOGENETICS; RANDOMIZED CONTROLLED TRIALS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY;

EID: 1242343609     PISSN: 03008878     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. Durant J, Clevenbergh P, Halfon P, Delgiudice P, Porsin S, Simonet P, et al. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet 1999; 353: 2195-9.
2. Baxter JD, Mayers BL, Wentworth DN, Neaton JD, Hoover ML, Winters MA, et al. A randomized study of antiretroviral management based on plasma genotypic resistance testing in patients failing therapy. AIDS 2000; 14: F83-93.
3. Tural C, Ruiz L, Holtzer C, Schapiro J, Viciana P, González J, et al. Clinical utility of HIV-1 genotyping and expert advice: the Havana trial. AIDS 2002; 16: 209-18.
4. Cingolani A, Antinori A, Rizzo MG, Murri R, Ammassari A, Baldini F, et al. Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA). AIDS 2002; 16: 369-79.
5. Calvin JC, Hunt S, Sension M, Farthing C, Conant M, Jacobson S, et al., VIRA3001 Study Team. A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. AIDS. 2002; 16: 579-88.
6. Meynard JL, Vray M, Morand-Joubert L, Race E, Descamps D, Peytavin G, et al. Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial. AIDS 2002; 16: 727-36.
7. Hirsch MS, Brun-Vezinet F, D'Aquila RT, Hammer SM, Johnson VA, Kuritzkes DR, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. JAMA 2000; 283: 2417-26.
8. The EuroGuidelines Group for HIV Resistance. Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting. AIDS. 2001: 15: 309-20.
9. International AIDS Society - USA Resistance Testing Guidelines Panel. Topics HIV Med 2001; 9: 31-3.
10. Schinazi RF, Larder B, Mellors JW. Int Antiviral News 2000; 8: 65-91.
11. Shafer RW, Jung DR, Betts BJ, Xi Y, Gonzales MJ. Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Res 2000; 28: 346-8.
12. DeGruttola V, Dix L, D'Aquila R, Holder D, Phillips A, Ait-Khaled M, et al. The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antivir Ther 2000; 5: 41-8.
13. Larder BA, Kemp SD, Hertogs K. Quantitative prediction of HIV-1 phenotypic drug resistance from genotypes: the virtual phenotype (VirtualPhenotype). Antivir Ther 2000; 5(Suppl 3): 49-50.
14. Menéndez-Arias L. Summary of mutations involved in resistance to antiretroviral drugs. In: Clotet B, Menéndez-Arias L, Ruiz L, Tural C, Brun Vezinet F, Loveday C, et al, eds. Guide to management of HIV drug resistance and pharmacokinetics of antiretroviral therapy, 2nd ed. Barcelona: TAISA; 2002. p. 196-202.
15. Van Laethem K, De Luca A, Antinori A, Cingolani A, Perno CF, Vandamme AM. A genotypic drug resistance interpretation algorithm that significantly predicts therapy response in HIV-infected patients. Antivir Ther 2002: 7: 123-9.
16. Boulmé R, Halfon P, Diaz R, Dugas O, Schmit JC. Comparative evaluation between five automated resistance interpretation algorithms. 5th International Workshop on HIV Drug Resistance and Treatment Strategies, Scottsdale, USA, 4-8 June 2001. Abstract 156. Antivir Ther 2001; 6(Suppl 1): 121.
17. Retrogram 1.6. www.retrogram.com
18. Visible Genetics. www.visgen.com and www.trugene.com/Physicians/GuideLineRules0.pdf Update at: http://www.trugene.com/Physicians/GuideLines_6.0_Rules.pdf
19. Reid C, Bassett R, Day S, Larder B, DeGruttola V, Winslow D. A dynamic rules-based interpretation system derived by an expert panel is predictive of virological failure. XI International HIV drug resistance workshop. Basic principles and clinical implications. Abstract 112. Antivir Ther 2002; 7(Suppl 1): S91.
20. Stanford website database. http://hivdb.stanford.edu
21. Hammer S, Peeters M, Harrihan R, Larder B. Virtual phenotype is predictive of treatment failure in treatment-experienced patients. 5th International Workshop on HIV Drug Resistance and Treatment Strategies, Scottsdale, USA, 4-8 June 2001. Antivir Ther 2001; 6(Suppl 1): 107.
22. Tibotec-Virco. www.vircolab.com
23. French government guidelines. http://www.sante.gouv.fr/htm/actu/rap_delf/4_genotype.htm Update at: http://perso.club-internet.fr/pugliese/index.htm
24. International Medical Press. http://www.mediscover.net/antiviralintro.cfm
25. Intelligent Therapeutic Solutions. http://www.therapyedge.com
26. Advanced Biological Laboratories. http://www.ablnetworks.org.
27. Los Alamos website resistance database. http://www.hiv.lanl.gov/ADRA/adra.html
28. Beerenwinkel N, Schmidt B, Walter H, Kaiser R, Lengauer T, Hoffmann D, et al. Diversity and complexity of HIV-1 drug resistance: a bioinformatics approach to predicting phenotype from genotype. Proc Natl Acad Sci USA 2002; 99: 8271-6.
29. AREVIR 'geno2pheno'. http://cartan.gmd.de/geno2pheno.html Update at: http://www.genafor.org
30. International AIDS Society-USA. http://hivinsite.ucsf.edu/medical/resistance/2098.474c.html Update at: http://www.iasusa.org/resistancetations/resistance.pdf
31. Specialty laboratories. www.specialtylabs.com
32. HIVresistanceWeb, Vertibrae. http://www.hivresistanceweb.com/protected/mutationtables/
33. Piketty C, Race E, Castiel P, Belec L, Peytavin C, Si-Mohamed A, et al. Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed a conventional triple-drug regimen: phenotypic resistance to protease inhibitors predicts outcome of therapy AIDS 1999; 12: F71-7.
34. Castagna A, Danese A, Hasson H, Boeri E, Lazzarin A, Peeters M, et al. The normalized inhibitory quotient (NIQ of lopinavir is predictive of viral load response over 48 weeks in a cohort of highly experienced HIV-infected individuals. 9th Conference on Retroviruses and Opportunistic Infections, Seattle, USA, 24-28 February 2002. Abstract 128.
35. Haubrich R, Keiser P, Kemper C, Witt M, Leedom J, Forthal D, et al. CCTG 575: a randomized, prospective study of phenotype testing versus standard of care for patients failing antiretroviral therapy. Antivir Ther 2001; 6(Suppl 1): 63.
36. Ravela J, Betts BJ, Brun-Vezinet F, Vandamme AM, Descamps D, van Laethem K, et al. HIV-1 protease and reverse transcriptase mutation patterns responsible for discordances between genotypic drug resistance interpretation algorithms. J Acquir Immune Defic Syndr 2003; 33: 8-14.
37. De Luca A, Cingolani A, Di Giambenedetto S, Trotta MP, Baldini F, Rizzo MG, et al. Variable prediction of antiretroviral treatment outcome by different systems for interpreting genotypic human immunodeficiency virus type 1 drug resistance. J Infect Dis 2003; 187: 1934-43.
38. Lanier R, Scott J, Ait-Khaled M, Stone C, Melby T, Sturge G, et al. Predicting abacavir antiviral activity using HIV-1 genotype: a comparison of 12 algorithms. 5th International Workshop on HIV Drug Resistance and Treatment Strategies, Scottsdale, USA, 4-8 June 2001. Antivir Ther 2001; 6(Suppl 1): 103.